Overview

Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2

Status:
Completed

Trial end date:
2007-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this noncomparative study is to obtain preliminary estimates of the efficacy of erlotinib and standard chemotherapy in patients with advanced, previously untreated nonsmall cell lung cancer (NSCLC) and an Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 2. The study will also evaluate the safety of single-agent erlotinib in this patient population.

Phase:

Phase 2

Details

Lead Sponsor:

OSI Pharmaceuticals

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Erlotinib Hydrochloride
Paclitaxel